Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 9 Carcinoma, Transitional Cell 4 Neoplasms 3 Neoplasm Metastasis 3 Breast Neoplasms 3 Ureteral Neoplasms 2 Urothelial Cancer 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Insufficiency 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Locally Advanced or Metastatic Unresectable Urothelial Cancer 1 Kidney Neoplasms 1

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 durvalumab 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Urothelial Cancer × vinflunine × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡